IVA vs JANX

Inventiva S.A. - American Depos vs Janux Therapeutics, Inc. — Valuation Comparison 2026

IVA

Biotechnology
Inventiva S.A. - American Depos
Quality
4.4
out of 10
Value Trap
6
SAFE
Price
$5.23
Last close
Models
7/13
Active
VS

JANX

Biotechnology
Janux Therapeutics, Inc.
Quality
5.4
out of 10
Value Trap
24
SAFE
Price
$14.74
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType IVA Fair ValueIVA Upside JANX Fair ValueJANX Upside
Bayesian DCF Intrinsic $0.59 -88.8% $4.28 -71.0%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $9.03 -38.7%
PWERM Option-Based $5.93 +13.4% $15.04 +2.0%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for IVA vs JANX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

IVA vs JANX — Which Stock Is More Undervalued?

JANX scores higher with a 5.4/10 quality rating vs IVA's 4.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Inventiva S.A. - American Depos (IVA) and Janux Therapeutics, Inc. (JANX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

IVA currently trades at $5.23 with a QOC of 4.4/10, while JANX trades at $14.74 with a QOC of 5.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).